Distalmotion develops and commercializes the DEXTER robotic surgery system, designed to bring the benefits of robotics to outpatient settings. The platform has been adopted in clinical practice across Europe and the United States, treating more than 3,000 patients to date. In the U.S., DEXTER holds FDA clearance for adult inguinal hernia repair, cholecystectomy, and benign hysterectomy. The company positions its technology as a cost-effective, versatile option aimed at expanding robotic surgery beyond large tertiary hospitals. Following a $150 million Series G round in 2025, Distalmotion continues to invest in scaling operations and advancing product development. The latest strategic backing from Johnson & Johnson Innovation – JJDC is expected to accelerate these growth initiatives. Distalmotion maintains its headquarters in Lausanne, Switzerland, with an additional office in Cleveland, Ohio. No revenue figures were disclosed in the article, but the patient count underscores growing clinical adoption.

Total raised

$390M

Funding rounds

5

Latest round

Series G

Latest activity

Nov 2025